A Phase 3 interventional study of Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live and Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck) in Measles, Mumps and Rubella, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 12 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.
134 studies on the registry are indexed under Measles; 17 are open to participants now.
This study's enrollment of 1,997 is above the median of 852 across 105 interventional studies indexed under Measles.
Browse Measles studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,166 studies on the registry; 132 are open to participants now.
Of its 501 completed or terminated interventional studies of FDA-regulated products, 370 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
M-M-R(TM) II at current release potency
Biological: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live · Biological: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
M-M-R(TM) II at intermediate expiry potency
Biological: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live · Biological: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
M-M-R(TM) II at expiry potency
Biological: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live · Biological: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
0.5 mL subcutaneous injection of one of three sub-lots on Day 0
0.5 mL subcutaneous injection on Day 0
Neutralizing antibodies to mumps at 6 weeks postvaccination
Time frame: 6 weeks postvaccination
Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination
Time frame: 6 weeks and 1 year postvaccination
No study locations are listed for this record.
The record gives a start of Feb 1999, a primary completion of Jul 2001 and a completion of Jul 2001. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.